Navigation Links
Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
Date:8/18/2010

BOULDER, Colo., Aug. 18 /PRNewswire/ -- Bolder BioTechnology, Inc. today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant totaling $600,000 from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH).  The grant will be used to demonstrate the feasibility of using our novel, long-acting IL-11 analog to accelerate platelet recovery and improve survival in a mouse model of Acute Radiation Syndrome (ARS).  Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

"Development of radiological/nuclear countermeasures to treat ARS is a high priority research area for NIAID," said George (Joe) Cox, Ph.D., Company President and Principal Investigator for the grant.  "We are delighted to receive a grant award from NIAID to conduct research with our long-acting IL-11 analog in ARS."  

Bone marrow is one of the most sensitive tissues to radiation damage and impaired production of blood cells is one of the first clinical signs of excessive radiation exposure, often resulting in death.  IL-11 is a protein that stimulates bone marrow cells to divide and differentiate into platelets.  Recent studies indicate that IL-11 can mitigate some of the hematopoietic and gastrointestinal complications of radiation exposure and improve survival in animal models of ARS.  IL-11 has a short half-life in humans, which necessitates daily dosing, and may not optimize therapeutic benefits of the protein for patients.  A long-acting IL-11 analog that does not require frequent dosing could provide significant treatment advantages in a nuclear emergency setting.

The NIH SBIR program is a peer-reviewed grant program that provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs.  

Bolder BioTechnolo
'/>"/>

SOURCE Bolder BioTechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
2. Kun Run Biotechnology Announces That They Have Obtained the Manufacturing Approval for Entecavir from the China State Food and Drug Administration
3. Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer
4. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
5. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
6. Derycz Scientific Featured in Pharmaceutical Manufacturing and Genetic Engineering & Biotechnology News
7. Americas Pharmaceutical Research and Biotechnology Companies Lead the Charge Toward Longer, Healthier Lives for Americans
8. PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract
9. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
10. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
11. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 2Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 3Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 4Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 5Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 6Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 7Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 8Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 9Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 10Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 11Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 12Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 13Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 14Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 15Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 16Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 17Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 18Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 19Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 20Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 2Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 3Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 4Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 5Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 6Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 7Abbott to Collaborate With GSK on Molecular Diagnostic Test to Select Candidate Patients for Future Skin Cancer Immunotherapy 8
(Date:7/25/2014)... As reported by the Statesman Journal in ... (7/20), police in Salem, MA as well as several ... recent heroin epidemic that has taken many lives during the ... overdose case in which police were able to make two ... By pretending to be the victim and claiming to want ...
(Date:7/25/2014)... NY (PRWEB) July 25, 2014 ... prices across the board for the Guinness International Champions ... and Olympiacos FC at Soldier Field on Sunday, ... offering their customer appreciation promo/coupon/offer code SOCCER-2014 for added ... amazing year for diehard soccer fans in North America. ...
(Date:7/25/2014)... -- Seniors are more easily distracted during thinking and ... "Almost any type of memory test administered reveals ... on," study co-author Randi Martin, professor of psychology at ... However, Martin said, this study shows that "environmental interference" ... compared with younger adults. The study included 60 ...
(Date:7/25/2014)... UT (PRWEB) July 25, 2014 ... surfaces for the recent Nike National Invitational Tournament ... current United States Junior National Tournament (USJN) ... 25. , The flooring for these prestigious national tournaments ... than 300,000 square feet of playing surface at McCormick ...
(Date:7/25/2014)... Reproductive Science Center (RSC) of New England ... Lead Physician at RSC Rhode Island, received the distinguished ... fertility care and community outreach issued by Providence Business ... Awards ceremony held July 24th at Salve Regina University ... regarded, emerging leaders in their field were recognized by ...
Breaking Medicine News(10 mins):Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Liverpool FC vs. Olympiacos FC Tickets Soldier Field: Ticket Down Slashes Ticket Prices for Guinness International Champions Cup in Chicago on Sunday, July 27th 2Health News:Distractions Seem More Troublesome With Age 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2
... in just one state, but a resurgence could occur, CDC ... As the H1N1 swine flu outbreak eases to a point ... health officials are still urging Americans to get their swine ... Week," Kathleen Sebelius, Secretary of the U.S. Department of Health ...
... , , , , MINNEAPOLIS, Jan. ... National Courage Award . Since 1980, Minnesota-based Courage ... an individual,s contributions to the health, welfare and rehabilitation of ... winners include: Max Cleland, Justin Dart Jr., Sen. Bob Dole, ...
... DHA boosted memory of Alzheimer,s patients in study , ... nutrients might help improve memory in Alzheimer,s patients by stimulating ... shows. , Uridine, choline and the omega-3 fatty acid DHA ... molecules that make up brain cell membranes, which form synapses. ...
... LAVAL, QC, Jan. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: ... draw down of $1 million under its standby equity distribution (SEDA) ... Labopharm issued 482,165 of its common shares to YA at a ... (All currency figures are in Canadian dollars.) , In accordance with ...
... ... at 32nd annual San Antonio Breast Cancer Symposium , ... Los Angeles, CA (PRWEB) January ... announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension ...
... low level X-rays, , FRIDAY, Jan. 8 (HealthDay News) ... airline flight approaching Detroit, officials have announced plans to increase ... some travelers wondering about the health effects of these devices. ... expose passengers to excess levels of radiation? Experts say no. ...
Cached Medicine News:Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 2Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 3Health News:Courage Center Seeks Nominations for 2010 National Courage Award 2Health News:Labopharm settles $1 million draw down under standby equity distribution agreement 2Health News:Labopharm settles $1 million draw down under standby equity distribution agreement 3Health News:Abraxis Provides Overview Of ABRAXANE Study 2Health News:Abraxis Provides Overview Of ABRAXANE Study 3Health News:Airport Full Body Scanners Pose No Health Threat: Experts 2Health News:Airport Full Body Scanners Pose No Health Threat: Experts 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: